Investment
Features
FeesSafety
Academy
More
Pluang+

Perella Weinberg reports Q2 2026 revenue up 1%, adjusted EPS $0.20, plans acquisition of Gleacher Shacklock.

Company Fundamentals
31 Jul 2026
Na
View Source
Bullish
pluang ai news

Perella Weinberg Partners reported Q2 2026 revenues of $157 million, a 1% increase from last year, with adjusted pre-tax income of $27 million and adjusted EPS of $0.20. Despite a 17% revenue decline in the first half of 2026, the firm is investing in senior talent and expects to complete the acquisition of Gleacher Shacklock in Q3. The company maintains a strong balance sheet with $116 million cash and no debt, returning $73 million to shareholders year-to-date. The focus remains on scaling the business through strategic hires and acquisitions.

More News

Novo Nordisk's ZEUS trial shows no cardiovascular event reduction with ziltivekimab in high-risk patients.

Novo Nordisk's ZEUS trial shows no cardiovascular event reduction with ziltivekimab in high-risk patients.

Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...

Company Fundamentals
Bearish
2 hours ago
Perella Weinberg promotes eight managing directors to partners, strengthening leadership across key sectors.

Perella Weinberg promotes eight managing directors to partners, strengthening leadership across key sectors.

Perella Weinberg Partners announced the promotion of eight managing directors to partners, recognizing their achievements and leadership in sectors like financial services, healthcare, and capital solutions. This move highlights the firm's confidence...

Company Fundamentals
Bullish
2 hours ago
Replimune stock jumps after Citigroup upgrade and positive FDA panel vote on melanoma drug

Replimune stock jumps after Citigroup upgrade and positive FDA panel vote on melanoma drug

Replimune Group's stock surged following Citigroup's upgrade to Overweight and a favorable FDA advisory panel vote supporting its advanced melanoma drug, RP1. The FDA panel voted 10-3 in favor of the drug's effectiveness in combination with nivolumab...

Market News
Bullish
3 hours ago
ICODA's Artem Voinov to attend Blockchain Rio 2026, highlighting Latin America's growing role in global Web3.

ICODA's Artem Voinov to attend Blockchain Rio 2026, highlighting Latin America's growing role in global Web3.

Artem Voinov, Chief Business Development Officer at ICODA, will attend Blockchain Rio 2026, Latin America's largest blockchain conference, held August 12–13 in Rio de Janeiro. The event gathers regulators, financial institutions, and Web3 leaders, em...

Market News
Bullish
3 hours ago
GM to launch a deeply integrated AI assistant tailored for vehicle use later this year

GM to launch a deeply integrated AI assistant tailored for vehicle use later this year

General Motors plans to introduce its own in-vehicle AI assistant later this year, designed to be more integrated with its vehicles than the current Google Gemini AI. This new assistant will combine conversational AI with GM vehicle knowledge and OnS...

Others
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App